AIM: To study the mechanism involved in the potentially beneficial effect of ultra low dose aspirin (ULDA) in prehepatic portal hypertension, rats were pretreated with selective COX 1 or 2 inhibitors (SC-560 or NS-398 respectively), and subsequently injected with ULDA or placebo. METHODS: Portal hypertension was induced by portal vein ligation. Platelet activity was investigated with an in-vivo model of laser induced thrombus production in mesenteric circulation and induced hemorrhagic time (IHT). Platelet aggregation induced by ADP and dosing of prostanoid products 6-keto-PGF1alpha, TXB2, PGE2 and LTB4 were also performed. RESULTS: The portal hypertensive group receiving a placebo showed a decreased in vivo platelet activity with prolonged IHT, an effect that was normalized by ULDA. SC-560 induced a mild antithrombotic effect in the normal rats, and an unmodified effect of ULDA. NS-398 had a mild prothrombotic action in portal hypertensive rats, similar to ULDA, but inhibited a further effect when ULDA was added. An increased 6-keto-PGF1alpha was observed in portal hypertensive group that was normalised after ULDA administration. TXA2 level after ULDA, remained unchanged. CONCLUSION: These results suggest that the effect of ULDA on platelet activity in portal hypertensive rats, could act through a COX 2 pathway more than the COX 1, predominant for aspirin at higher doses.
AIM: To study the mechanism involved in the potentially beneficial effect of ultra low dose aspirin (ULDA) in prehepatic portal hypertension, rats were pretreated with selective COX 1 or 2 inhibitors (SC-560 or NS-398 respectively), and subsequently injected with ULDA or placebo. METHODS: Portal hypertension was induced by portal vein ligation. Platelet activity was investigated with an in-vivo model of laser induced thrombus production in mesenteric circulation and induced hemorrhagic time (IHT). Platelet aggregation induced by ADP and dosing of prostanoid products 6-keto-PGF1alpha, TXB2, PGE2 and LTB4 were also performed. RESULTS: The portal hypertensive group receiving a placebo showed a decreased in vivo platelet activity with prolonged IHT, an effect that was normalized by ULDA. SC-560 induced a mild antithrombotic effect in the normal rats, and an unmodified effect of ULDA. NS-398 had a mild prothrombotic action in portal hypertensiverats, similar to ULDA, but inhibited a further effect when ULDA was added. An increased 6-keto-PGF1alpha was observed in portal hypertensive group that was normalised after ULDA administration. TXA2 level after ULDA, remained unchanged. CONCLUSION: These results suggest that the effect of ULDA on platelet activity in portal hypertensiverats, could act through a COX 2 pathway more than the COX 1, predominant for aspirin at higher doses.
Authors: J E Fabre; M Nguyen; K Athirakul; K Coggins; J D McNeish; S Austin; L K Parise; G A FitzGerald; T M Coffman; B H Koller Journal: J Clin Invest Date: 2001-03 Impact factor: 14.808
Authors: M A Potenza; O A Botrugno; M A De Salvia; G Lerro; C Nacci; F L Marasciulo; R Andriantsitohaina; D Mitolo-Chieppa Journal: Am J Physiol Gastrointest Liver Physiol Date: 2002-09 Impact factor: 4.052
Authors: Yukihiro Yokoyama; Balazs Toth; William C Kitchens; Martin G Schwacha; Kirby I Bland; Irshad H Chaudry Journal: Am J Physiol Gastrointest Liver Physiol Date: 2003-12 Impact factor: 4.052
Authors: N J Skill; N G Theodorakis; Y N Wang; J M Wu; E M Redmond; J V Sitzmann Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-09-04 Impact factor: 4.052